In situ modeling of acquired resistance to RTK/RAS-pathway-targeted therapies

Nancy E. Sealover(Uniformed Services University of the Health Sciences), Robert L. Kortum(Uniformed Services University of the Health Sciences)
iScience
December 11, 2023
10.1016/j.isci.2023.108711
Cited by 14

Related Papers

A Phospholipase C-γ1–Independent, RasGRP1-ERK–Dependent Pathway Drives Lymphoproliferative Disease in Linker for Activation of T Cells–Y136F Mutant Mice
|The Journal of Immunology|2012|17
Wild-type RAS signaling is an essential therapeutic target in <i>RAS</i> -mutated cancers
|Science Signaling|2025|3
In situ modeling of acquired resistance to RTK/RAS pathway targeted therapies
|bioRxiv (Cold Spring Harbor Laboratory)|2023|2
SOS1 inhibition suppresses the emergence of osimertinib resistance to generate a durable response in <i>EGFR</i> -mutant lung cancer
|Science Signaling|2025|2